|Mr. Greg Duncan||Chairman & CEO||779.32k||N/A||1965|
|Ms. Angela Walsh||CFO, SVP of Fin., Corp. Sec. & Treasurer||253.45k||N/A||1967|
|Mr. Ralph D. Grosswald M.P.H.||Sr. VP of Operations||233.95k||N/A||1969|
|Ms. Carol Duffy Ph.D.||Chief Scientific Advisor||N/A||N/A||N/A|
|Dr. R. Michael Gendreau||Chief Medical Officer||N/A||N/A||1956|
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was incorporated in 2012 and is headquartered in Alpharetta, Georgia.
Virios Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.